Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares ...

NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, ...

Novo Nordisk A/S (NVO) on Wednesday reported second-quarter profit of $4.03 billion. On a per-share basis, the Bagsvaerd, ...

Novo Nordisk A/S NVO reported second-quarter 2025 earnings of 97 cents per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 93 cents. The company had reported earnings of ...

Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below ...

Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...

January 01, 2025 — 09:00 am EST Written by Zacks Equity Research for Zacks -> Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks.

Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a mini-rally that extended into Friday; the company's share price added nearly 5% ...

For Immediate ReleaseChicago, IL – May 10, 2023 – Zacks Equity Research shares Novo Nordisk A/S NVO as the Bull of the Day and Nutrien NTR as the Bear of the Day. In addition, Zacks Equity ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...